Organoids Global Market Report 2024

These organoids come in various forms such as hepatic, colorectal, and intestinal, among others. Hepatic organoids, for instance, represent fully functional in vitro models of the liver. They play a pivotal role in addressing an array of research queries related to hepatic development, regeneration, and disease modeling.

These groundbreaking tools harness different sources, including pluripotent stem cells and organ-specific adult stem cells. They find application across developmental biology, infectious disease pathology, regenerative medicine, drug efficacy and toxicity testing, as well as drug discovery and personalized medicine.
Their adoption spans a wide spectrum, encompassing hospitals, diagnostic centers, biotechnology and pharmaceutical companies, and other industries seeking to leverage their immense potential for advancements in healthcare and research.

The organoids market research report provides organoids market statistics, including organoids industry global market size, regional shares, competitors with a organoids market share, detailed organoids market segments, market trends, and opportunities, and any further data you may need to thrive in the organoids industry. This organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organoids market has grown exponentially in recent years. It will grow from $1.42 billion in 2023 to $1.78 billion in 2024 at a compound annual growth rate (CAGR) of 25.1%. The expansion observed during the historical period can be credited to progress in biomedical research, the evolving demands of drug discovery and development, the necessity for disease modeling, the rising popularity of personalized medicine, and the supportive regulatory environment.

The organoids market is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2028 at a compound annual growth rate (CAGR) of 25.2%. Anticipated growth in the forecast period is likely due to a surge in chronic disease rates, advancements in genome editing techniques, an upswing in stem cell research, collaborative ventures and partnerships, and intensified efforts in clinical translation.

The anticipated rise in chronic and infectious diseases is projected to drive growth in the organoid market. Organoids, used for studying these diseases and treatments, offer rapid and reliable insights into pathogen biology and drug screening. As of January 2023, the National Center for Biotechnology Information forecasts a nearly 99.5% increase in the U.S. population over 50 with chronic diseases, from 71.522 million in 2020 to an estimated 142.66 million by 2050, affirming the market's growth trajectory due to heightened chronic disease prevalence.

The escalating number of clinical trials aimed at drug development is set to fuel the expansion of the organoid market. These trials, totaling 452,604 globally as of May 17, 2023, registered on ClinicalTrials.gov - an increase from over 365,000 trials in early 2021, underscore the growing utilization of organoids. Leveraged in modeling diseases and refining personalized medicine, organoids play a pivotal role in advancing scientific understanding and improving patient care, solidifying their contribution to market growth.

Technological advancements stand as a prominent trend shaping the organoid market. Companies within this sector continuously introduce cutting-edge technologies to fortify their market positions. Notably, in March 2023, MIMETAS unveiled the OrganoReady product line featuring a novel adult stem cell-derived tubular organoid, harnessing innovative technology for mechanistic toxicology and drug-induced organ injury assessments. Developed on the patented microfluidic platform, OrganoPlate, these perfused 3D structures demonstrate the industry's commitment to pioneering advancements in organoid technologies.

Market leaders prioritize the development of pioneering platforms such as organoid panel screening, driving progress in preclinical oncology drug discovery. For example, in November 2023, Crown Bioscience launched OrganoidXplore, a revolutionary large-scale organoid panel screening platform. Utilizing their AR organoid technology, this platform streamlines preclinical drug discovery by offering reliable drug response comparisons that faithfully replicate original tumors' genomic, morphological, and pathophysiological characteristics. With enhanced performance and cost-effectiveness, OrganoidXplore signals a significant stride in accelerating oncology drug discovery.

In December 2022, Molecular Devices LLC, a UK-based research and development company, acquired Cellesce Ltd. for an undisclosed amount. The acquisition will provide Molecular Devices LLC with Cellesce Ltd human-derived cell or organoid lines and strengthen the company's position as a 3D biology solutions innovator. Cellesce Ltd is a UK-based company with expertise in cell expansion focused on organoids.

Major companies operating in the organoids market report are Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, 3Dnamics Inc., OcellO B.V., Organoid Therapeutics, PeproTech Inc., QGel SA, Corning Incorporated, Thermo Fisher Scientific, Trevigen Inc., Path BioAnalytics, R&D Systems, Merck KGaA, 3D BioMatrix Inc., 3D Biotek LLC, AMS Biotechnology (Europe) Limited, Greiner Bio-One, 3-D Matrix, InSphero AG, Synthego Corporation, Axol Bioscience Ltd., TissUse GmbH, CytoSMART Technologies BV, EMD Millipore Corporation, Epithelix Sàrl.

North America was the largest region in the organoids market in 2023. Asia-pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in the organoids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The organoids market consists of sales of epithelial organoid, embryonic organoid, and cerebral organoid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.